Concurrent chemoradiotherapy combined with immunotherapy is superior to traditional concurrent chemoradiotherapy in the treatment of advanced cervical cancer

Purpose of investigation: In advanced cervical cancer, traditional therapy included concurrent chemoradiotherapy (CCRT), pelvic radiotherapy, and brachytherapy. In the last few years, the development of using of immunotherapy (IMT), targeted therapy, angiogenesis inhibitors, and tyrosine kinase inhibitors encourage us to provide better treatment choices in advanced cervical cancer patients. In this study, the authors propose CCRT combined with immunotherapy (ICRT) as a better treatment option for advanced cervical cancer. Materials and Methods: The authors retrospectively reviewed the medical records of 23 patients with advanced cervical who were treated by CCRT or ICRT between 2000 and 2016 at Chang Gung Memorial Hospital. In CCRT group (total 15 cases), patients were treated with traditional platinum-based chemotherapy and radiotherapy. In ICRT group (total eight cases), patients were treated with CCRT and adjuvant IMT. The authors chose Picibanil (OK-432) plus interleukin-2 (IL-2) for adjuvant IMT. Between CCRT and ICRT groups, they analyzed the difference of age, histological type of cervical cancer, follow-up period, recurrence rate, and diagnosis-to-recurrence period between them. They also analyzed the difference of complete blood cell counts and its differentiating counts after one month of treatment. Results: Within these parameters, the recurrence rate between ICRT and CCRT group showed significant difference (37.5% vs. 86.67%, p = 0.0257). The authors observed that diagnosis to recurrence duration was longer in ICRT group than CCRT group (67.32 months vs. 11.92 months, p = 0.1464), although there was no statistical significance found. The laboratory findings one month after treatment showed significant difference in absolute lymphocyte counts (ALC), which showed 1,554.23/μL vs. 577.38 /μL (mean value, p = 0.0011) in ICRT and CCRT group respectively. Conclusions: This study indicated that CCRT combined with immunotherapy is superior to traditional CCRT in treatment of advanced cervical cancer.

Cervical cancer; Concurrent chemoradiotherapy; Immunotherapy

[1] Adegoke O., Kulasingam S., Virnig B.: “ Cervical cancer trends in the United States: a 35-year population-based analysis”. J. Womens. Health. (Larchmt.), 2012, 21, 1031.

[2] Park Y., Vongdala C., Kim J., Ki M.: “Changing trends in the incidence (1999-2011) and mortality (1983-2013) of cervical cancer in the Republic of Korea”. Epidemiol. Health, 2015, 37, e2015024.

[3] Rygaard C.: “The Danish Quality Database for Cervical Cancer Screening”. Clin. Epidemiol., 2016, 8, 655.

[4] Baldur-Felskov B., Munk C., Nielsen T.S., Dehlendorff C., Kirschner B., Junge J., et al.: “Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997-2012”. Cancer Causes Control, 2015, 26, 1105.

[5] Perkins A.C., Skinner E.N.: “A Review of the Current Cervical Cancer Screening Guidelines”. N. C. Med. J., 2016, 77, 420.

[6] Nygard J.F., Skare G.B., Thoresen S.O.: “The cervical cancer screening programme in Norway, 1992-2000: changes in Pap smear cov- erage and incidence of cervical cancer”. J. Med. Screen., 2002, 9, 86.

[7] Lai C.H.: “Management of recurrent cervical cancer”. Chang. Gung. Med. J., 2004, 27, 711.

[8] Elit L., Fyles A.W., Devries M.C., Oliver T.K., Fung-Kee-Fung M.: “Gynecology Cancer Disease Site G. Follow-up for women after treatment for cervical cancer: a systematic review”. Gynecol. Oncol., 2009, 114, 528.

[9] Bodurka-Bevers D., Morris M., Eifel P.J., Levenback C., Bevers MW., Lucas KR., et al.: “Posttherapy surveillance of women with cervical cancer: an outcomes analysis”. Gynecol. Oncol., 2000, 78, 187.

[10] Teh J., Yap S.P., Tham I., Sethi VK., Chua EJ., Yeo R., et al.: “Con- current chemoradiotherapy incorporating high-dose rate brachytherapy for locally advanced cervical carcinoma: survival outcomes, patterns of failure, and prognostic factors”. Int. J. Gynecol. Cancer, 2010, 20, 428.

[11] Ma R., Zhang H., Zou L., Qu Y.: “Outcomes and prognostic factors of distant metastasis in patients with advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy”. Zhonghua. Fu. Chan. Ke. Za. Zhi., 2015, 50, 125.

[12] Kawaguchi R., Furukawa N., Kobayashi H., Asakawa I.: “Posttreatment cut-off levels of squamous cell carcinoma antigen as a prog- nostic factor in patients with locally advanced cervical cancer treated with radiotherapy”. J. Gynecol. Oncol., 2013, 24, 313.

[13] Finn O.J.: “Cancer immunology”. N. Engl. J. Med., 2008, 358, 2704.

[14] Spellman A., Tang S.C.: “Immunotherapy for breast cancer: past, present, and future”. Cancer Metastasis Rev., 2016, 35, 525.

[15] Clark J.I, Wong M.K, Kaufman H.L, Daniels GA., Morse MA., Mc- Dermott DF., et al.: “Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM”. Clin. Genitourin. Cancer, 2017, 15, 31.e4

[16] Johansson H., Andersson R., Bauden M., Hammes S., Holdenrieder S., Ansari D.: “Immune checkpoint therapy for pancreatic cancer”. World. J. Gastroenterol., 2016, 22, 9457.

[17] Charmsaz S., Al-Ejeh F., Yeadon T., Miller KJ., Smith F., Stringer B., et al.: “EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia”. Leukemia, 2017, Jan 31. doi: 10.1038/ leu.2016.371. [Epub ahead of print]

[18] Nakamura K., Hanazawa S., Takeda T., Sumiyoshi R., Kobayashi S., Takeda H., et al.: “The effect of immunotherapy and hyperthermia on advanced or recurrent ovarian and uterine cancer - 229 clinical cases]”. Gan. To. Kagaku. Ryoho., 2014, 41, 1295.

[19] Tewari K.S., Monk B.J.:” New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy”. Clin. Cancer. Res., 2014, 20, 5349.

[20] Song M., DiPaola R.S., Cracchiolo B.M., Gibbon DG., Hellmann M., Nieves-Neira W., et al.: “Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer”. Int. J. Gynecol. Cancer, 2014, 24, 1636.

[21] Fujimoto K., Tomonaga M., Goto S.: “A case of recurrent ovarian cancer successfully treated with adoptive immunotherapy and lentinan”. Anticancer. Res., 2006, 26, 4015.

[22] Woopen H., Pietzner K., Darb-Esfahani S., Oskay-Oezcelik G., Sehouli J.: “Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature”. Med. Oncol., 2012, 29, 3416.

[23] Shimizu A., Hondoh T., Watanabe S., Moriyama S., Yoshida K., Miyakawa Z., et al.: “A case report: ovarian carcinoma IVth can become complete remission by immunochemotherapy”. Gan. To. Kagaku. Ryoho., 1994, 21, 2346.

[24] Shimizu A., Watanabe S., Okuyama D., Morioka M., Yoda A., Hoshino K., et al.: “A case report: complete remission of stage IV uterine cervix carcinoma by immuno-chemotherapy with intraarterial infusion using implantable reservoir system”. Gan. To. Kagaku. Ryoho., 1995, 22, 1706.

[25] Egyed M., Kollar B., Prievara F.T., Viski A., Bajzik G., Pajor L., et al.: “Successful treatment of a primary uterine B-cell lymphoma with rituximab-CHOP immunochemotherapy”. Haematologica, 2007, 92, e26.

[26] Lorin L., Bertaut A., Hudry D., Beltjens F., Roignot P., Bone-Lepinoy MC., et al.: “About invasive cervical cancer: a French population based study between 1998 and 2010”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2015, 191, 1.

[27] Harsh K.K., Kapoor A., Paramanandhan M., Narayan S., Purohit R., Kumari P., et al.: “Induction chemotherapy followed by concurrent chemoradiation in the management of different stages of cervical carcinoma: 5-year retrospective study”. J. Obstet. Gynaecol. India, 2016, 66, 372.

[28] Usami T., Takahashi A., Matoda M., Okamoto S., Kondo E., Kanao H., et al.: “Review of Treatment and Prognosis of Stage IVB Cervical Carcinoma”. Int. J. Gynecol. Cancer, 2016, 26, 1239.

[29] Oei A.L., van Leeuwen C.M., ten Cate R., Rodermond HM., Buist MR., Stalpers LJ., et al.:” Hyperthermia selectively targets human papillomavirus in cervical tumors via p53-dependent apoptosis”. Cancer. Res., 2015, 75, 5120.

[30] Crezee J., van Leeuwen C.M., Oei A.L., van Heerden LE., Bel A., Stalpers LJ., et al.: “Biological modelling of the radiation dose escalation effect of regional hyperthermia in cervical cancer”. Radiat. Oncol., 2016, 11, 14.

[31] Chen C.Y., Lai C.H., Yang L.Y., Tang YH., Chou HH., Chang CJ., et al.:” Immunomodulatory therapy in refractory/recurrent ovarian cancer”. Taiwan. J. Obstet. Gynecol., 2015, 54, 143.

[32] Ryoma Y., Moriya Y., Okamoto M., Kanaya I., Saito M., Sato M.: “Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy”. Anticancer. Res., 2004, 24, 3295.

[33] Okamoto M., Oshikawa T., Tano T., Ahmed SU., Kan S., Sasai A., et al.:” Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling”. J. Immunother., 2006, 29, 78.

[34] Ahmed S.U., Okamoto M., Oshikawa T., Tano T., Sasai A., Kan S., et al.:” Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti- cancer drug, and OK-432, a streptococcal immunopotentiator: involvement of toll-like receptor 4”. J. Immunother., 2004, 27, 432.

[35] Ono T., Kurata S., Wakabayashi K., Sugawara Y., Saito M.: “Inhibitory effect of a streptococcal preparation (OK-432) on the nucleic acid synthesis in tumor cells in vitro”. Gan., 1973, 64, 59.

[36] Mizumoto K., Niihara H., Kusatake K., Morita E.:” Stage IV malignant melanoma successfully treated with OK-432 and percutaneous ethanol injection therapy after mass reduction surgery”. J. Dermatol., 2014, 41, 1129.

[37] Tian Y.F., Tang K., Guan W., Yang T., Xu H., Zhuang QY., et al.: “OK-432 suppresses proliferation and metastasis by tumor associated macrophages in bladder cancer”. Asian. Pac. J. Cancer. Prev., 2015, 16, 4537.

[38] Noda K., Teshima K., Tekeuti K., Hasegawa K., Inoue K., Yamashita K., et al.: “Immunotherapy using the streptococcal preparation OK- 432 for the treatment of uterine cervical cancer. Cervical Cancer Immunotherapy Study Group”. Gynecol. Oncol., 1989, 35, 367.

[39] Gorai I., Yanagibashi T., Minaguchi H.: “Immunological modulation of lymphocyte subpopulation in cervical cancer tissue by sizofiran and OK-432”. Gynecol. Oncol., 1992, 44, 137.